C C McGown1, N J Brown, P G Hellewell, C S Reilly, Z L S Brookes. 1. Microcirculation Research Group, Department of Cardiovascular Sciences, University of Sheffield, Faculty of Medicine, Dentistry and Health, Beech Hill Road, Sheffield S10 2RX, UK.
Abstract
BACKGROUND: Sepsis induces microvascular inflammation and production of the vasodilator nitric oxide (NO) via endothelial and inducible nitric oxide synthase (eNOS or NOS III and iNOS or NOS II). Statins are cholesterol-lowering drugs; however, they also attenuate inflammation. This study aimed to determine whether pravastatin protected against sepsis-induced hypotension, loss of vascular tone, and microvascular inflammation via NOS pathways. METHODS: Male Wistar rats (n=18) were anaesthetized and the mesentery prepared for fluorescent intravital microscopy. Animals received either lipopolysaccharide (LPS; n=6); LPS+pravastatin (18 and 3 h before LPS; n=6), or saline as a control, for 4 h. RESULTS: Mean arterial pressure decreased in LPS-treated animals (P<0.05), but not in those also receiving pravastatin. Acetylcholine-induced relaxation of venules was abolished by LPS but improved by pravastatin. Pravastatin also reduced the increase in nitrite concentration and macromolecular leak from venules induced by LPS (P<0.05). The increased leucocyte adhesion seen in LPS-treated rats was also reduced in those also treated with pravastatin. Immunohistochemical analysis showed that pravastatin increased endothelial cell expression of NOS III during sepsis, but had no effect on LPS-induced up-regulation of NOS II. CONCLUSIONS: Pravastatin improved NOS III-mediated vessel relaxation and exerted anti-inflammatory effects within the microcirculation after LPS administration in rats. Pravastatin therefore appears to have beneficial effects during sepsis, as a result of increased microvascular expression and function of NOS III.
BACKGROUND:Sepsis induces microvascular inflammation and production of the vasodilator nitric oxide (NO) via endothelial and inducible nitric oxide synthase (eNOS or NOS III and iNOS or NOS II). Statins are cholesterol-lowering drugs; however, they also attenuate inflammation. This study aimed to determine whether pravastatin protected against sepsis-induced hypotension, loss of vascular tone, and microvascular inflammation via NOS pathways. METHODS: Male Wistar rats (n=18) were anaesthetized and the mesentery prepared for fluorescent intravital microscopy. Animals received either lipopolysaccharide (LPS; n=6); LPS+pravastatin (18 and 3 h before LPS; n=6), or saline as a control, for 4 h. RESULTS: Mean arterial pressure decreased in LPS-treated animals (P<0.05), but not in those also receiving pravastatin. Acetylcholine-induced relaxation of venules was abolished by LPS but improved by pravastatin. Pravastatin also reduced the increase in nitrite concentration and macromolecular leak from venules induced by LPS (P<0.05). The increased leucocyte adhesion seen in LPS-treated rats was also reduced in those also treated with pravastatin. Immunohistochemical analysis showed that pravastatin increased endothelial cell expression of NOS III during sepsis, but had no effect on LPS-induced up-regulation of NOS II. CONCLUSIONS:Pravastatin improved NOS III-mediated vessel relaxation and exerted anti-inflammatory effects within the microcirculation after LPS administration in rats. Pravastatin therefore appears to have beneficial effects during sepsis, as a result of increased microvascular expression and function of NOS III.
Authors: Xiaohong Shu; T C Stevenson Keller; Daniela Begandt; Joshua T Butcher; Lauren Biwer; Alexander S Keller; Linda Columbus; Brant E Isakson Journal: Cell Mol Life Sci Date: 2015-08-25 Impact factor: 9.261
Authors: Gang Zhou; George Kamenos; Suresh Pendem; John X Wilson; Feng Wu Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-11-23 Impact factor: 3.619
Authors: Alessandro Morandi; Christopher G Hughes; Timothy D Girard; Danny F McAuley; E Wesley Ely; Pratik P Pandharipande Journal: Chest Date: 2011-09 Impact factor: 9.410
Authors: Caroline C McGown; Zoë L S Brookes; Paul G Hellewell; Jonathan J Ross; Nicola J Brown Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-02-14 Impact factor: 3.000
Authors: Alessandro Morandi; Christopher G Hughes; Jennifer L Thompson; Pratik P Pandharipande; Ayumi K Shintani; Eduard E Vasilevskis; Jin H Han; James C Jackson; Daniel T Laskowitz; Gordon R Bernard; E Wesley Ely; Timothy D Girard Journal: Crit Care Med Date: 2014-08 Impact factor: 7.598
Authors: Zoë L S Brookes; Lewis Ruff; Viralkumar S Upadhyay; Linghong Huang; Sony Prasad; Tirupa Solanky; Surya M Nauli; Albert C M Ong Journal: Am J Physiol Heart Circ Physiol Date: 2012-10-26 Impact factor: 4.733
Authors: Dale M Needham; Elizabeth Colantuoni; Victor D Dinglas; Catherine L Hough; Amy W Wozniak; James C Jackson; Peter E Morris; Pedro A Mendez-Tellez; E Wesley Ely; Ramona O Hopkins Journal: Lancet Respir Med Date: 2016-01-29 Impact factor: 30.700